FAES FARMA, SA

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.

Phase 3

Not yet recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: Mesalazine

First Posted Date: 2023-12-19

Last Posted Date: 2023-12-19

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 376

Registration Number: NCT06176560

Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids

Phase 3

Terminated

Conditions: Haemorrhoids Without Complication

Interventions: Drug: Placebo
Drug: Hemorrane plus
Drug: Hemorrane

First Posted Date: 2023-03-29

Last Posted Date: 2024-02-28

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 21

Registration Number: NCT05788497

Locations: 🇪🇸
CS Dr. Mendiguchia Carriche, Leganés, Madrid, Spain
🇪🇸
CAP Can Bou, Castelldefels, Barcelona, Spain
🇪🇸
CAPSBE Les Corts, L'Hospitalet de Llobregat, Barcelona, Spain

and more 10 locations

Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Placebo
Drug: Bilastine

First Posted Date: 2021-03-23

Last Posted Date: 2023-03-16

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 59

Registration Number: NCT04810390

Locations: 🇪🇸
Instituto Oftálmologico Quironsalud A Coruña, A Coruña, Spain
🇪🇸
Hospital Universitari German Trias i Pujol (HGTiP),, Badalona, Spain
🇪🇸
Hospital Universitari Dexeus, Barcelona, Spain

and more 15 locations

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency

Phase 2

Completed

Conditions: Vitamin D Deficiency
Vitamin D Insufficiency

Interventions: Drug: Calcifediol 100mcg
Other: Placebo
Drug: Calcifediol 75mcg
Drug: Calcifediol 125mcg

First Posted Date: 2021-02-03

Last Posted Date: 2023-09-15

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 674

Registration Number: NCT04735926

Locations: 🇸🇰
KK Neuro, s.r.o., Neurologická ambulancia, Žilina, Slovakia
🇪🇸
Hospital Universitario Rio Hortega, Valladolid, Spain
🇪🇸
Hospital Quirónsalud Barcelona, Barcelona, Spain

and more 52 locations

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Ketotifen Ophthalmic Solution 0.025% (Zaditen)
Drug: Vehicle of Bilastine Ophthalmic Solution
Drug: Bilastine Ophthalmic Solution 0.6%

First Posted Date: 2018-03-27

Last Posted Date: 2023-03-16

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 228

Registration Number: NCT03479307

Locations: 🇺🇸
East West Eye Institute, Torrance, California, United States
🇺🇸
Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States
🇺🇸
Apex Eye, Mason, Ohio, United States

and more 3 locations

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Phase 2

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Bilastine 0.2%
Drug: Bilastine 0.6%
Drug: Bilastine 0%
Drug: Bilastine 0.4%

First Posted Date: 2017-07-27

Last Posted Date: 2023-03-16

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 121

Registration Number: NCT03231969

Locations: 🇺🇸
Ora Clinical Research Center, Andover, Massachusetts, United States

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

Phase 3

Completed

Conditions: Perennial Allergic Rhinitis

Interventions: Drug: Placebo
Drug: Bilastine
Drug: Cetirizine

First Posted Date: 2010-05-21

Last Posted Date: 2012-09-26

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 650

Registration Number: NCT01127620

Oral Bioavailability of Bilastine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bilastine

First Posted Date: 2010-05-14

Last Posted Date: 2012-09-26

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 12

Registration Number: NCT01124123

Locations: 🇪🇸
Unidad de Investigacion Clinica. Clinica Universidad de Navarra, Pamplona, Navarra, Spain

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Placebo
Drug: Bilastine
Drug: Desloratadine

First Posted Date: 2010-04-22

Last Posted Date: 2012-04-05

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 720

Registration Number: NCT01108783

Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)

Phase 1

Completed

Conditions: Allergic Rhinoconjunctivitis
Chronic Urticaria

Interventions: Drug: Bilastine

First Posted Date: 2010-03-05

Last Posted Date: 2012-09-26

Lead Sponsor: Faes Farma, S.A.

Target Recruit Count: 36

Registration Number: NCT01081574

Locations: 🇩🇪
Universitäts-Hautklinik, Kiel, Germany
🇦🇺
Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia
🇦🇺
Royal Children's Hospital, Parkville, Victoria, Australia

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy